DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Masimo's (MASI) New Product Expansion to Boost Patient Outcome
by Zacks Equity Research
Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.
DexCom (DXCM) to Boost Diabetes Management With New Approval
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.
Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario
by Zacks Equity Research
Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation
by Zacks Equity Research
Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.
Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCG
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
DexCom (DXCM) Q4 Earnings Lag Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH
by Urmimala Biswas
Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.
The Markets' Tone: Cautiously Optimistic
by Daniel Laboe
As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Earnings Preview: DexCom (DXCM) Q4 Earnings Expected to Decline
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $435.04, marking a +1.06% move from the previous day.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Why DexCom (DXCM) Could Beat Earnings Estimates Again
by Zacks Equity Research
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DexCom (DXCM) Posts Solid Preliminary Q4 and 2021 Revenues
by Zacks Equity Research
DexCom (DXCM) posts solid fourth-quarter and full-year 2021 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.
Should iShares Russell MidCap ETF (IWR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWR
Should Vanguard MidCap Growth ETF (VOT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOT
Should Vanguard MidCap ETF (VO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VO
Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCB
4 Internet of Medical Things (IoMT) Stocks to Buy for 2022
by Riya Anand
Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.